Dr. Atkins Discusses Response to Atezolizumab in RCC

Michael B. Atkins, MD
Published: Tuesday, Aug 15, 2017



Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma (RCC).

Data presented by David McDermott, MD, showed that there was a relationship between tumor microenvironment factors and efficacy with atezolizumab in RCC.

In the tumors that were T-effector high and myeloid low, atezolizumab alone or with bevacizumab (Avastin) showed better efficacy compared with sunitinib (Sutent). Conversely, in the T-effector high, myeloid-high subset, atezolizumab monotherapy did poorly, but did well with the addition of bevacizumab. This suggests that bevacizumab enhances the immune responsiveness of atezolizumab, says Atkins.
 


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma (RCC).

Data presented by David McDermott, MD, showed that there was a relationship between tumor microenvironment factors and efficacy with atezolizumab in RCC.

In the tumors that were T-effector high and myeloid low, atezolizumab alone or with bevacizumab (Avastin) showed better efficacy compared with sunitinib (Sutent). Conversely, in the T-effector high, myeloid-high subset, atezolizumab monotherapy did poorly, but did well with the addition of bevacizumab. This suggests that bevacizumab enhances the immune responsiveness of atezolizumab, says Atkins.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x